Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Molecular Targets
A Computational And In Vitro Appraisal Of Ostarine To Target Androgen Receptor In Glioma C6 Cells.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Molecular Targets
A Computational And In Vitro Appraisal Of Ostarine To Target Androgen Receptor In Glioma C6 Cells.

Related Experiment Video

Evaluation of Stem Cell Properties in Human Ovarian Carcinoma Cells Using Multi and Single Cell-based Spheres Assays

Evaluation of Stem Cell Properties in Human Ovarian Carcinoma Cells Using Multi and Single Cell-based Spheres Assays

Published on: January 3, 2015

A Computational and In Vitro Appraisal of Ostarine to Target Androgen Receptor in Glioma C6 Cells.

Satvika Sharma¹, Sandeep Saini^1,2, Vijayta Dani Chadha³

¹Department of Biophysics, Panjab University, Chandigarh, India.

Cell Biochemistry and Biophysics

|June 13, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Selective androgen receptor modulators (SARMs) show promise for glioma treatment. Ostarine (MK-2866) effectively inhibits glioma C6 cells by targeting the androgen receptor (AR), offering a potential new therapy.

Keywords:

Androgen receptor Glioma Ostarine SARM

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Experiment Videos

Evaluation of Stem Cell Properties in Human Ovarian Carcinoma Cells Using Multi and Single Cell-based Spheres Assays

Evaluation of Stem Cell Properties in Human Ovarian Carcinoma Cells Using Multi and Single Cell-based Spheres Assays

Published on: January 3, 2015

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Area of Science:

Neuro-oncology
Molecular Endocrinology
Cancer Therapeutics

Background:

Gliomas are primary brain tumors originating from glial cells, representing the majority of central nervous system (CNS) malignancies.
Androgen receptor (AR) signaling is implicated in tumor growth and altered in various cancers, including glioma.
Targeting AR for glioma treatment is of interest, but traditional antagonists are limited by glioma's heterogeneity.

Purpose of the Study:

To investigate the potential of selective androgen receptor modulators (SARMs) as a therapeutic strategy for glioma.
To evaluate the binding affinity and efficacy of SARMs against glioma cells.
To identify a SARM with promising anti-glioma activity.

Main Methods:

Computational screening of 20 SARMs using AutoDock vina for binding affinity analysis.

Molecular dynamics (MD) simulations and MM-PBSA analysis to assess binding stability.

In vitro assays including IC50 determination, cell viability, migration, and invasion assays using C6 glioma cells.

Main Results:

Ostarine (MK-2866) demonstrated high binding affinity (-9.4 Kcal/mol) to the AR N-terminal domain (NTD).
MD simulations and MM-PBSA confirmed strong and stable binding of Ostarine to AR.
Ostarine showed a twofold increase in C6 cell inhibition compared to Bicalutamide and reduced cell viability, migration, and invasion.

Conclusions:

Ostarine acts as a potent AR antagonist with significant chemotherapeutic potential against glioma.
SARMs, exemplified by Ostarine, represent a promising therapeutic avenue for managing glioma propagation.
Further studies are warranted to explore Ostarine's efficacy in more aggressive glioma models.